





# Assessing the effectiveness of ADMiRE, Ireland's first early access specialist service for ADHD in children and adolescents

J Keane<sup>1</sup>, B. Cawley<sup>1</sup>, K. Mulholland<sup>1</sup>, S. Killeen<sup>1</sup>, S. Watters<sup>1</sup>, L. Healion<sup>1</sup>, M. Grace<sup>1</sup>, J. Colclough<sup>1</sup>, R. Buckmaster<sup>1</sup>, R. McCann<sup>1</sup>, D. McTiernan<sup>1</sup>, J. McGrath<sup>1,2</sup>

1. ADMiRE, Linn Dara CAMHS, Health Service Executive, Ireland, 2. Department of Psychiatry, Trinity College Dublin, Ireland. Corresponding author: jane.mcgrath@tcd.ie

# **Background & Objectives**

- One-third of children attending Child Mental Health Services (CAMHS) in Ireland have a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). CAMHS are currently overwhelmed with urgent referrals, and "routine" ADHD assessments are often significantly delayed. Set up in 2019, ADMiRE offers early access to a structured assessment/intervention protocol for young people who are referred to CAMHS with likely ADHD, similar to the Dundee Clinical Care Pathway (Coghill and Seth, 2015) but tailored for an Irish healthcare population.
- The research objectives were 1. To determine adherence to international standards for high-quality ADHD care in ADMiRE, and 2. to assess the overall effectiveness of the ADMiRE service in optimization of ADHD treatment.

## Methods


• Files of all young people attending ADMiRE were audited annually over a four-year period in January (2019, 2020, 2021 and 2022). The audit questionnaire investigated adherence to standards obtained from NICE guidelines for diagnosis/management of ADHD (NG87), and included additional information about demographics, diagnosis (including comorbidities), assessment, ADHD severity and pharmacological treatment. The audit data was analysed to investigate adherence to NG87 standards, and to compare progress and trends between 2019 and 2022.

## Results


#### **Demographics and Co-occurring difficulties** Comorbidity Attachment difficulties Sensory processing difficulties Age range (n=196) 13 Learning difficulties Motor difficulties (DCD) Language difficulties Likely ASD ASD diagnosis Sex 5% 10% 15% 20% 25% **Female** 18% Caseload in January 2023 was 196 young people Male:Female ratio ~4:1 Age range: 6-18 82% Comorbidity levels are very high, in particular with neurodevelopmental disorders, behavioural disorders and anxiety disorders. There has been little change in overall demographics, but an increased recognition of co-morbidity since 2019 Adherence to standards Centile charts in file? **Standardised forms used?** Physical assessment is Standardised ADMiRE completed on 100% forms are used in 9 of 10 young people. children attending. Centile charts are Significant improvement YES YES present in file for 87%. 89% since 2019. 87% **Parent ADHD severity Teacher ADHD severity** monitoring monitoring Parents provided ADHD Teachers have provided symptom severity ratings NO feedback about ADHD NO 5% 29% (every 6/12) for 96% symptom severity in young people with ADHD 100% of young people YES who are on ADHD 71% pre-assessment and in YES 96% medication. Significant 71% for follow up. improvement since 2019 Significant improvement since 2019

# **Optimisation of caseload**

- Between 2019 and 2021 (3 years)
  81% of the caseload were optimised on ADHD treatment.
- In 2022 (one year), 50% of the caseload were optimised on ADHD treatment
- These young people now attend routine follow up clinics on a 3-6 monthly basis with their CAMHS team.




## **Medication** use



## **Key points:**

- 71% of the current caseload have moved through the assessment phase and are being treated with ADHD medication.
- Over the past 4 years
   Methylphenidate has been the most
   commonly prescribed ADHD
   medication
- 45% of young people attending ADMiRE are on Melatonin for sleep difficulties



# Conclusion

- Over the past 5 years, ADMiRE has pioneered the development of effective, efficient and safe ADHD service provision in the public health service in Ireland.
- The clinical care pathway in ADMiRE is very effective and reduces risk. Service user satisfaction is very high, it facilitates rapid training of rotating doctors, and there is interest in implementing the ADMiRE protocol nationally
- This 4 year audit demonstrates ongoing optimisation of the ADMiRE model of care with year-on-year improvements in adherence to international standards
- Planned digital transformation of the ADMiRE model has recently been funded by the Irish government in collaboration with the HSE ICT and Digital Health Department and HSE Digital Transformation team. This transformation will increase accessibility and scalability of the ADMiRE clinical care pathway nationally.



